{
    "clinical_study": {
        "@rank": "31872", 
        "arm_group": {
            "arm_group_label": "Leadless Pacemaker", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Prospective, non-randomized, single-arm, international multicenter, clinical safety and\n      effectiveness investigation."
        }, 
        "brief_title": "The LEADLESS II IDE", 
        "condition": "Subjects Who Are Indicated for a VVI(R) Pacemaker.", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subject must have one of the clinical indications in adherence with Medicare,\n             ACC/AHA/HRS/ESC single chamber pacing guidelines including:\n\n               -  Chronic and/or permanent atrial fibrillation with 2 or 3\u00b0 AV or bifascicular\n                  bundle branch block (BBB block), including slow ventricular rates (with or\n                  without medication) associated with atrial fibrillation; or\n\n               -  Normal sinus rhythm with 2 or 3\u00b0 AV or BBB block  and a low level of physical\n                  activity or short expected lifespan (but at least one year); or\n\n               -  Sinus bradycardia with infrequent pauses or unexplained syncope with EP\n                  findings; and\n\n          2. Subject \u226518 years of age; and\n\n          3. Subject has life expectancy of at least one year; and\n\n          4. Subject is not enrolled in another clinical investigation; and\n\n          5. Subject is willing to comply with clinical investigation procedures and agrees to\n             return for all required follow-up visits, tests, and exams; and\n\n          6. Subject has been informed of the nature of the study, agrees to its provisions and\n             has provided written informed consent, approved by the IRB; and\n\n          7. Subject is not pregnant and does not plan to get pregnant during the course of the\n             study.\n\n        Exclusion Criteria:\n\n          1. Subject has pacemaker syndrome, has retrograde VA conduction or suffers a drop in\n             arterial blood pressure with the onset of ventricular pacing; or\n\n          2. Subject is allergic or hypersensitive to <1 mg of dexamethasone sodium phosphate; or\n\n          3. Subject has a mechanical tricuspid valve prosthesis; or\n\n          4. Subject has a pre-existing pulmonary arterial (PA) hypertension (PA systolic pressure\n             exceeds 40 mmHg or RV systolic pressure (RVSP) as estimated by echo exceeds 40 mmHg),\n             or significant physiologically-impairing lung disease; or\n\n          5. Subject has a pre-existing pacing or defibrillation leads; or\n\n          6. Subject has current implantation of either conventional or subcutaneous implantable\n             cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT); or\n\n          7. Subject has an implanted vena cava filter; or\n\n          8. Subject has evidence of thrombosis in one of the veins used for access during the\n             procedure; or\n\n          9. Subject has an implanted leadless cardiac pacemaker."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "667", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02030418", 
            "org_study_id": "DC-02374"
        }, 
        "intervention": {
            "arm_group_label": "Leadless Pacemaker", 
            "intervention_name": "Leadless Pacemaker", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 1, 2014", 
        "location": {
            "contact": {
                "email": "vivek.reddy@mountsinai.org", 
                "last_name": "Vivek Reddy, MD", 
                "phone": "212-741-7272"
            }, 
            "contact_backup": {
                "email": "srinivas.dukkipati@mountsinai.org", 
                "last_name": "Srinivas Dukkipati, MD", 
                "phone": "(212) 741-7272"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10029"
                }, 
                "name": "Mount Sinai Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Safety and Effectiveness Trial for the Nanostim Leadless Pacemaker", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Complication-Free Rate", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Pacing thresholds and R-wave amplitudes within the therapeutic range", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02030418"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "appropriate and proportional rate response during graded exercise testing", 
            "safety_issue": "No", 
            "time_frame": "3-6 months"
        }, 
        "source": "St. Jude Medical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "St. Jude Medical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}